Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Lyumjev Summary of Product Characteristics (SmPC)
Lyumjev® ▼ (insulin lispro): Injection Site Edema
In the PRONTO-T2D study, 1 patient treated with Lyumjev experienced edema at the injection site and was discontinued from the study.
Edema at Injection Site in Phase 3 Studies - PRONTO-T1D and PRONTO-T2D
In the PRONTO-T1D study, no patient experienced edema at the injection site.1
In the PRONTO-T2D study, 1 patient (0.3%) treated with Lyumjev experienced moderate edema at the injection site on the initial day of use, which was considered by the investigator to be related to study drug. The patient was discontinued from the study approximately 3.5 months after the start of the investigational product. The event was consider unresolved at the last visit of the trial.1
Phase 3 Studies - PRONTO-T1D and PRONTO-T2D
The phase 3 efficacy and safety studies were designed to compare Lyumjev with IL-100 in patients with T1DM (PRONTO-T1D) and in patients with T2DM (PRONTO-T2D).2,3
The PRONTO-T1D and PRONTO-T2D studies were randomized, double-blind, controlled, treat-to-target comparisons of Lyumjev and IL-100, both in combination with either IGlar or IDeg in adults with T1DM and T2DM, respectively.4
The PRONTO-T1D study was a 3-treatment group design study that included
2 treatment groups that were administered Lyumjev and IL-100 immediately (0-2 minutes) prior to each meal in a double-blind manner, and
a third open-label treatment group that was administered Lyumjev 20 minutes after the start of a meal.1,2
The PRONTO-T2D study consisted of 2 treatment groups where Lyumjev and IL-100 were administered immediately (0-2 minutes) prior to each meal in a double-blind manner.1,3
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. Klaff LJ, Cao D, Dellva MA, et al. Ultra rapid lispro (URLi) improves postprandial glucose (PPG) control vs. Humalog (lispro) in T1D: PRONTO-T1D study [abstract 144-OR]. Diabetes. 2019;68(suppl 1). http://dx.doi.org/10.2337/db19-144-OR
3. Blevins T, Zhang Q, Frias JP, et al. Ultra rapid lispro (URLi) improves postprandial glucose (PPG) control vs. Humalog (lispro) in patients with type 2 diabetes (T2D): PRONTO-T2D [abstract 145-OR]. Diabetes. 2019;68(suppl 1). http://dx.doi.org/10.2337/db19-145-OR
4. Results from two phase 3 studies show Lilly's ultra rapid lispro (URLi) met primary efficacy endpoint in people with type 1 and type 2 diabetes. Press release. Eli Lilly and Company; October 2, 2018. Accessed June 18, 2020. http://lilly.mediaroom.com/index.php?s=9042&item=137825
Glossary
IDeg = insulin degludec
IGlar = insulin glargine
IL-100 = Humalog® (insulin lispro injection) 100 units/mL
PRONTO-T1D = a Prospective, Randomized, double-blind cOmparison of LY900014 to iNsulin lispro with an open-label postprandial LY900014 Treatment group, in cOmbination with insulin glargine or insulin degludec, in adults with Type 1 Diabetes
PRONTO-T2D = a Prospective, Randomized, double-blind cOmparison of LY900014 to iNsulin lispro, boTh in cOmbination with insulin glargine or insulin degludec in adults with Type 2 Diabetes
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: January 17, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays